Sinoway Industrial Co., Ltd.

Lenalidomide - Metabolism and Excretion Lenalidomide - Metabolism and Excretion

Vitro studies shows that lenalidomide ( CAS: 191732-72-6) is not the substrate for liver metabolic enzymes. Lenalidomide prototype drug is the main component in the human body's circulation. There are two identified metabolites: 5-hydroxyl-lenalidomide and N-acetyl-lenalidomide. The concentration of each metabolite is less than 5% of the prototype drug level in the cycle.

About 90% and 4% of the radioactive doses are removed from urine and feces after giving a single dose of [14C]- lenalidomide ( CAS: 191732-72-6, 25mg) per os to the healthy subjects. About 82% of the radioactive dose is unmetabolized lenalidomide prototype drug, almost of which is excreted by urinary tract. The 5-hydroxyl-lenalidomide and N-acetyl-lenalidomide respectively account for 4.59% and 1.83% of the excretion dose. The renal clearance rate of the lenalidomide is higher than the glomerular filtration rate, so there is at least some degree of active secretion about the lenalidomide ( CAS: 191732-72-6) .

In the recommended dose range (5 ~ 25mg/day), the plasma half-life of healthy subjects and multiple myeloma patients is approximately 3 hours and 3 to 5 hours respectively.

Sinoway, the best lenalidomide manufacturer from China, devoted itself to supplying high quality lenalidomide with good price. Click here to buy lenalidomide
Related News
  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//